Protocols

Soon-Shiong blasts back at “maliciously false” STAT story; ImmunoMet raises $5M

→ Badly wounded by a report from STAT that he essentially funneled revenue to his company through a charitable gift to the University of Utah, Patrick Soon-Shiong is firing back in the LA Times, saying the story is “maliciously false.” He adds that he gave the money to the university out of a “desire to make this knowledge available to scientists throughout the world.” The report carved out a big chunk of NantHealth’s share price $NH earlier in the week. Soon-Shiong is the second largest shareholder in the company that owns the LA Times.

→ Houston-based ImmunoMet Therapeutics raised $5 million in a Series B financing with participation from Intervest, SL Investment, NHN Investment along with the Series A investors Mirae Asset Venture Investments, GNTech and Dr. Sung-wuk Kim, founder, chairman and CEO of ImmunoMet.

→ The microcap penny stock biotech Heat Biologics $HBTX has come up with a deal to buy Austin-based Pelican Therapeutics, agreeing to pay up to $500,000 for an 80% share of the company.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy




EvaluatePharma World Preview 2017